SELLAS Life Sciences Reports Completion Of Enrollment In Phase 1/2 Trial Of GPS In Combo With Pembrolizumab In Advanced Metastatic Ovarian Cancer
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis
Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17
46 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 158.2% to $7.23 after tumbling 18% on Wednesday. Indonesia Energy said it projects to commence drilling of 2 back-to-back new wells within 30 days and a third by mid-year.
Sellas Life Sciences Shares Jump As China Approves Galinpepimut IND For Blood Cancer
China's National Medical Products Administration (NMPA)
SELLAS Life Sciences Announced IND Acceptance for First Clinical Trial of GPS in China
SELLAS Life Sciences Group, Inc.
70 Biggest Movers From Friday
Gainers
Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
SELLAS Life Sciences Reports Settlement Of Derivative Litigation
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of
SELLAS Life Sciences Q2 EPS $(0.30) Up From $(0.66) YoY
SELLAS Life Sciences (NASDAQ:SLS) reported quarterly losses of $(0.30) per share. This is a 54.55 percent increase over losses of $(0.66) per share from the same period last year.